A patient is getting a check up from a doctor who is using a dermatoscope in a GP surgery.
Health professionals

Last reviewed: 1 July 2026

Managing suspected skin cancer in primary care

A summary of the clinical guidelines, diagnostic aids and teledermatology pathways that support the diagnosis of skin cancer.

Last reviewed: 1 July 2026

An overview of skin cancer types

There are two main types of skin cancer – melanoma and non-melanoma.

Melanoma

Melanoma is rarer than non-melanoma skin cancer, but it is more likely to metastasise quickly and has a higher mortality rate. Melanoma incidence rates have increased by around 25% over the past decade in the UK. Fortunately, earlier diagnosis can increase the chance of survival. Almost all people diagnosed with stage 1 melanoma will survival five years, whereas around 7 in 10 people will survival 5 years when diagnosed at stage 3.

Non-melanoma skin cancer

Non-melanoma skin cancer is much more common with around 204,000 new cases in England each year. There are two main types of non-melanoma skin cancer: basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC). In almost all cases, BCC is treatable and rarely metastasises. cSCC can metastasise but survival outcomes are good when it's diagnosed early.

Who is most at risk of skin cancer?

The following groups of people are at greater risk of developing skin cancer:

  • People aged 85 to 89 (for melanoma skin cancer in the UK) and people aged 90 or above (for non-melanoma skin cancer in England) as incidence rates are highest in these age groups.

  • People who are immunosuppressed (such as transplant patients) or those with certain chronic conditions like HIV.

  • People with lighter skin tones as they have less melanin to protect them against sun damage. In the UK, almost 9 in 10 melanoma skin cancer cases are caused by too much exposure to UV.

Be aware that people with darker skin tones have a greater risk of developing a type of melanoma which more commonly presents on areas of the skin not normally exposed to the sun (e.g. palms, feet, nail beds). GPs can investigate these lesions using the key tips and resources below.

Your GP practice can use our free Sun Smart resources to help the public learn about sun safety and take steps to reduce their risk of skin cancer.

Tools to help GPs recognise and refer suspected melanoma cases

It can be challenging to distinguish skin cancer from other skin lesions. National guidelines provide tools that can help GPs across the UK to recognise and refer suspected melanoma cases.

The weighted 7-point checklist

The weighted 7-point checklist features in NICE NG12 guidelines. It advises GPs to refer people on an urgent suspected skin cancer pathway if they have a suspicious pigmented skin lesion that scores 3 or more.

This is a caption table example

Major features of the lesion (score 2 points each):

Minor features of the lesions (score 1 point each):

Change in size

Largest diameter 7mm or more

Irregular shape

Inflammation

Irregular colour

Oozing

Change in sensation

The ABCDE mnemonic

The ABCDE mnemonic in the Scottish Referral Guidelines (SRG) helps clinicians identify characteristics of concerning lesions.

Moles with the following should be referred to the local skin cancer pathway as a USC (urgent suspicion of cancer):

  • Asymmetry

  • Border irregularity

  • Colour irregularity

  • Diameter increasing or >6mm

  • Evolution in shape, size or colour

You can find images of melanoma and non-melanoma skin cancers in our key tips and resources section below. These can help you assess your patient and decide whether to refer.

Teledermatology pathways

GPs can use teledermatology pathways to support timelier diagnosis. This may involve taking macro and dermatoscopic images of skin lesions that are then sent for remote assessment by secondary care specialists. Remote clinical assessment may be used before or as part of an urgent suspected cancer referral.

Consider the following if you’ve been trained to take the macro and dermatoscopic images and have access to teledermatology pathways:

  • Take images using this method instead of using images provided by patients, which won’t be as high-quality and are inadequate for clinical assessment.

  • Be aware that secondary care professionals will not examine patients physically and are unable to palpate lesions.

  • Teledermatology pathways are not suitable for multiple lesions or lesions in intimate or difficult to photograph areas.

  • If your patient doesn’t need further investigation, ask them to get back in touch if they notice any changes to the size, shape or colour of a skin lesion.

  • Pathways will vary by region and nation.

Navy icon of the UK with Northern Ireland highlighted in magenta.

Northern Ireland has implemented the Dermatology Photo Triage pathway, which is an enhanced triage pathway.

If available, GPs should use their iPhone with the SmartDerm app and dermatoscope attachment to take and upload images for referral. Visit GPNI for pathway training resources.

The emerging role of AI in teledermatology pathways

There are ongoing evaluations exploring if AI technologies can be incorporated into teledermatology pathways to support the assessment and triage of skin lesions. In May 2025, NICE recommended using the AI technology DERM in NHS teledermatology services under specific conditions while further evidence is generated.

We will update this section to reflect developments in AI and teledermatology.

Key tips and resources

We have provided a list of handy tips and resources to support the recognition, referral and management of patients with suspected skin cancer.

  • Melanoma is most commonly found on the trunk in men and the legs in women.

  • Read NICE NG12, SRG and NICaN guidance information on the types of skin lesions that require referral. Consult local guidance and pathways too.

  • Where available, use advice and guidance services and expertise from practice colleagues to inform your assessment if you’re unsure of next steps or if lesions don’t meet the referral criteria.

  • Visit the Primary Care Dermatology Society and DermNet for useful decision-support tools.

  • If you're a GP in Scotland, you can find information and training resources on digital dermatology here.

  • Visit our safety netting hub for top tips on practicing robust safety netting.

  • Visit our public-facing webpages for images of non-melanoma skin cancer lesions and melanoma skin cancer lesions.

  • For more diverse images of melanoma, including subtypes, visit DermNet’s melanoma webpage.

Patient information

You can also direct your patients to our public-facing materials to help them reduce their risk of skin cancer and learn more about the disease:

References

  1. Arrow return up icon

    Cancer Research UK. Melanoma skin cancer statistics. Accessed 2026

  2. Arrow return up icon

    NHS England, Five-year Melanoma skin cancer survival (2016-2020). 2023.

  3. Arrow return up icon

    NDRS Get Data Out. Based on the average annual number of new cases of non-melanoma skin cancer (Keratinocyte cancer) in England in the years 2019, 2021-2022.

  4. Arrow return up icon

    Cancer Research UK. Survival for non melanoma skin cancer. Accessed 2026

  5. Arrow return up icon

    Based on the age-specific incidence rate per 100,000 people for non-melanoma skin cancer (ICD10 C44) in England in the years 2019, 2021-2022.

  6. Arrow return up icon

    Cancer Research UK. Risks and causes of melanoma skin cancer. Accessed 2026

  7. Arrow return up icon

    Cancer Research UK. Risks and causes of non melanoma skin cancer. Accessed 2026

  8. Arrow return up icon

    Calculated by the Cancer Intelligence Team at Cancer Research UK, 2024. UV-attributable cancer cases in the UK, 2003-2023. Available upon request.

  9. Arrow return up icon

    Surveillance, Epidemiology, and End Results (SEER) Program: SEER*Stat Database. National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, Website. seer.cancer.gov

  10. Arrow return up icon

    Markovic  SNErickson  LARao  RD  et al. Melanoma Study Group of the Mayo Clinic Cancer Center, Malignant melanoma in the 21st Century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis.  Mayo Clin Proc 2007;82 (3) 364- 380

  11. Arrow return up icon
  12. Arrow return up icon
  13. Arrow return up icon
  14. Arrow return up icon

    British Association of Dermatologists. Teldermatology. Accessed 2026